Information on EC 2.3.1.26 - sterol O-acyltransferase

New: Word Map on EC 2.3.1.26
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Search Reference ID:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Opisthokonta

EC NUMBER
COMMENTARY hide
2.3.1.26
-
RECOMMENDED NAME
GeneOntology No.
sterol O-acyltransferase
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
acyl-CoA + cholesterol = CoA + cholesterol ester
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Acyl group transfer
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
Steroid biosynthesis
-
-
sterol:steryl ester interconversion (yeast)
-
-
SYSTEMATIC NAME
IUBMB Comments
acyl-CoA:cholesterol O-acyltransferase
The animal enzyme is highly specific for transfer of acyl groups with a single cis double bond that is nine carbon atoms distant from the carboxy group.
CAS REGISTRY NUMBER
COMMENTARY hide
9027-63-8
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
African green monkey
-
-
Manually annotated by BRENDA team
pigeon
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
inbred strains with high/low response in low-density lipoprotein cholesterol to dietary cholesterol and fat, resp.
-
-
Manually annotated by BRENDA team
Mus musculus C57B1/6
C57B1/6
-
-
Manually annotated by BRENDA team
Rattus norvegicus male Sprague-Dawley
male Sprague-Dawley strain
-
-
Manually annotated by BRENDA team
Rattus norvegicus male Wistar
male Wistar strain
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
-
mice lacking ACAT1 or ACAT2 do not have a decreased PREG ester contents in adrenals, nor do they have altered levels of the three major secreted adrenal steroids in serum; mice lacking ACAT1 or ACAT2 do not have a decreased pregnenolone ester contents in adrenals, nor do they have altered levels of the three major secreted adrenal steroids in serum
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
acetyl-CoA + cholesterol
CoA + cholesteryl acetate
show the reaction diagram
-
16% of the activity with oleoyl-CoA
-
?
acyl-CoA + cholesterol
CoA + cholesterol ester
show the reaction diagram
docosahexaenoyl-CoA + cholesterol
CoA + cholesteryl docosahexanoate
show the reaction diagram
-
rate of cholesteryl ester formation is faster and more cholesteryl ester is formed with oleic acid compared to docosahexanoic acid. Docosahexanoic acid substantially reduces cholesteryl ester formation when given in combination with oleic acid
-
-
?
elaidoyl-CoA + cholesterol
CoA + cholesteryl elaidate
show the reaction diagram
-
-
-
?
lauroyl-CoA + cholesterol
CoA + cholesteryl laurate
show the reaction diagram
-
62% of the activity with oleoyl-CoA
-
?
linelaidoyl-CoA + cholesterol
CoA + cholesteryl linelaidate
show the reaction diagram
-
-
-
?
linoleoyl-CoA + cholesterol
CoA + cholesteryl linoleate
show the reaction diagram
long-chain fatty acyl-CoA + cholesterol
CoA + cholesterol ester
show the reaction diagram
myristoyl-CoA + cholesterol
CoA + cholesteryl myristate
show the reaction diagram
-
37% of the activity with oleoyl-CoA
-
?
oleoyl-CoA + 4alpha-methylcholest-7-en-3beta-ol
CoA + 4alpha-methylcholest-7-en 3-oleate
show the reaction diagram
oleoyl-CoA + 4alpha-methylcholest-7-en-3beta-ol
CoA + oleate ester of 4alpha-methylcholest-7-en-3beta-ol
show the reaction diagram
-
-
-
?
oleoyl-CoA + 5alpha,6alpha-epoxycholesterol
CoA + 5alpha,6alpha-epoxycholesteryl oleate
show the reaction diagram
-
activity comparable to cholesterol
-
-
?
oleoyl-CoA + 5alpha-cholest-8(14)-en-3beta-ol-15-one
CoA + cholestanyl oleate
show the reaction diagram
oleoyl-CoA + 5alpha-cholest-8(14)-en-3beta-ol-15-one
CoA + oleate ester of 5alpha-cholest-8(14)-en-3beta-ol-15-one
show the reaction diagram
oleoyl-CoA + 7alpha-hydroxycholesterol
CoA + 7alpha-hydroxycholesteryl oleate
show the reaction diagram
-
activity comparable to cholesterol
-
-
?
oleoyl-CoA + campesterol
CoA + campesteryl oleate
show the reaction diagram
oleoyl-CoA + cholest-4-en-3beta-ol
CoA + cholest-4-en 3-oleate
show the reaction diagram
oleoyl-CoA + cholestanol
CoA + cholestanyl oleate
show the reaction diagram
oleoyl-CoA + cholesterol
?
show the reaction diagram
oleoyl-CoA + cholesterol
CoA + cholesterol oleate
show the reaction diagram
-
-
-
-
?
oleoyl-CoA + cholesterol
CoA + cholesteryl oleate
show the reaction diagram
oleoyl-CoA + desmosterol
CoA + desmosteryl oleate
show the reaction diagram
oleoyl-CoA + episterol
CoA + episteryl oleate
show the reaction diagram
-
62% of the activity with cholesterol
-
?
oleoyl-CoA + ergosterol
CoA + ergosteryl oleate
show the reaction diagram
oleoyl-CoA + fecosterol
CoA + fecosteryl oleate
show the reaction diagram
-
48% of the activity with cholesterol
-
?
oleoyl-CoA + lanosterol
CoA + lanosteryl oleate
show the reaction diagram
-
65% of the activity with cholesterol
-
?
oleoyl-CoA + lathosterol
CoA + lathosteryl oleate
show the reaction diagram
oleoyl-CoA + sitosterol
CoA + cholesteryl oleate
show the reaction diagram
-
-
-
-
?
oleoyl-CoA + sitosterol
CoA + sitosterol oleate
show the reaction diagram
-
-
-
-
?
oleoyl-CoA + zymosterol
CoA + zymosteryl oleate
show the reaction diagram
-
93% of the activity with cholesterol
-
?
oleyl-CoA + cholesterol
?
show the reaction diagram
palmitoleoyl-CoA + cholesterol
CoA + cholesteryl palmitoleate
show the reaction diagram
-
91% of the activity with oleoyl-CoA
-
?
palmitoyl-CoA + cholesterol
CoA + cholesteryl palmitate
show the reaction diagram
pregnenolone + oleyl CoA
?
show the reaction diagram
stearoyl-CoA + cholesterol
CoA + cholesteryl stearate
show the reaction diagram
stearyl-CoA + cholesterol
CoA + cholesteryl stearate
show the reaction diagram
-
-
-
?
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
acyl-CoA + cholesterol
CoA + cholesterol ester
show the reaction diagram
long-chain fatty acyl-CoA + cholesterol
CoA + cholesterol ester
show the reaction diagram
additional information
?
-
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Ca2+
-
stimulates
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl (9Z,12E)-octadeca-9,12-dienoate
-
-
(1R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl 3-methylbutanoate
-
-
(1R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl benzoate
-
-
(1R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl butanoate
-
-
(1R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl pent-4-enoate
-
-
(1R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl pentanoate
-
-
(1R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl propanoate
-
-
(1R,3R,7R)-1-[(1S)-1-hydroxypropyl]-3,7-diphenyl-6-[(1S)-1-phenylethyl]-2-oxa-6-azaspiro[3.3]heptan-5-one
-
45% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested
(1R,3R,7S)-1-[(1S)-1-hydroxypropyl]-3,7-diphenyl-6-[(1S)-1-phenylethyl]-2-oxa-6-azaspiro[3.3]heptan-5-one
(1S)-1-[(1R,3R,5R)-3,5-diphenyl-6-[(1S)-1-phenylethyl]-2-oxa-6-azaspiro[3.3]hept-1-yl]propan-1-ol
-
0.01 mM, 45% inhibition
(24R)-ethylcholest-5-ene-3,7-diol
-
-
(3R,5R,7R,8S)-7-ethyl-8-hydroxy-3,5-diphenyl-2-[(1S)-1-phenylethyl]-6-oxa-2-azaspiro[3.4]octan-1-one
-
0.01 mM, 23% inhibition
(3R,5S,7S,8R)-7-ethyl-8-hydroxy-3,5-diphenyl-2-[(1R)-1-phenylethyl]-6-oxa-2-azaspiro[3.4]octan-1-one
-
27% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested
(3S,4R,4aS,6S,6aS,12R,12aR,12bR)-12,12b-dihydroxy-4,6a-dimethyl-4-[[(methylsulfonyl)oxy]methyl]-11-oxo-6-(pentanoyloxy)-9-pyridin-3-yl-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromen-3-yl benzoate
-
; selective for isoform ACAT2
(3S,4R,4aS,6S,6aS,12R,12aR,12bR)-12,12b-dihydroxy-4,6a-dimethyl-4-[[(methylsulfonyl)oxy]methyl]-11-oxo-9-pyridin-3-yl-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromene-3,6-diyl dipentanoate
-
; selective for isoform ACAT2
(3S,4R,4aS,6S,6aS,12R,12aR,12bR)-3-(acetyloxy)-4-[(acetyloxy)methyl]-12,12b-dihydroxy-4,6a-dimethyl-11-oxo-9-pyridin-3-yl-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromen-6-yl 3-methylbutanoate
-
; selective for isoform ACAT2
(3S,4R,4aS,6S,6aS,12R,12aR,12bR)-4-[(acetyloxy)methyl]-12,12b-dihydroxy-4,6a-dimethyl-11-oxo-9-pyridin-3-yl-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromene-3,6-diyl diacetate
-
; i.e. pyripyropene A,selective for isoform ACAT2
(3S,4R,4aS,6S,6aS,12R,12aR,12bR)-4-[(acetyloxy)methyl]-3-(butanoyloxy)-12,12b-dihydroxy-4,6a-dimethyl-11-oxo-9-pyridin-3-yl-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromen-6-yl hexanoate
-
; selective for isoform ACAT2
(3S,4S)-3-[(1R,2R)-2-azido-1-hydroxybutyl]-3-bromo-4-phenyl-1-[(1S)-1-phenylethyl]azetidin-2-one
-
65% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested
(3S,4S)-3-[(1S,2S)-2-azido-1-hydroxybutyl]-3-bromo-4-phenyl-1-[(1S)-1-phenylethyl]azetidin-2-one
-
60% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested
(3S,4S,4aR,6S,6aS,12R,12aR,12bR)-3-(acetyloxy)-4-[(acetyloxy)methyl]-4,12,12b-trihydroxy-6a-methyl-11-oxo-9-pyridin-3-yl-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromen-6-yl (2E)-pent-2-enoate
-
; selective for isoform ACAT2
(3S,5R,7R,8S)-7-ethyl-8-hydroxy-3,5-diphenyl-2-[(1S)-1-phenylethyl]-6-oxa-2-azaspiro[3.4]octan-1-one
-
0.01 mM, 27% inhibition
(3S,5S,7S,8R)-7-ethyl-8-hydroxy-3,5-diphenyl-2-[(1R)-1-phenylethyl]-6-oxa-2-azaspiro[3.4]octan-1-one
-
23% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested
(4aR,4bS,6S,6aS,12R,12aR,12bR,14aS)-12,12b-dihydroxy-4a,6a-dimethyl-2-(1-methylethyl)-11-oxo-9-pyridin-3-yl-4,4a,4b,5,6,6a,12,12a,12b,13,14,14a-dodecahydro-11H-pyrano[4',3':2,3]chromeno[6,5-f][1,3]benzodioxin-6-yl pentanoate
-
; selective for isoform ACAT2
(4aR,4bS,6S,6aS,12R,12aR,12bR,14aS)-12,12b-dihydroxy-4a,6a-dimethyl-2-(2-methylphenyl)-11-oxo-9-pyridin-3-yl-4,4a,4b,5,6,6a,12,12a,12b,13,14,14a-dodecahydro-11H-pyrano[4',3':2,3]chromeno[6,5-f][1,3]benzodioxin-6-yl pentanoate
-
; selective for isoform ACAT2
(4aR,4bS,6S,6aS,12R,12aR,12bR,14aS)-12,12b-dihydroxy-4a,6a-dimethyl-2-(4-methylphenyl)-11-oxo-9-pyridin-3-yl-4,4a,4b,5,6,6a,12,12a,12b,13,14,14a-dodecahydro-11H-pyrano[4',3':2,3]chromeno[6,5-f][1,3]benzodioxin-6-yl pentanoate
-
; selective for isoform ACAT2
(4S)-3-[(1R,2S)-2-azido-1-hydroxybutyl]-3-[(R)-hydroxy(phenyl)methyl]-4-phenyl-1-[(1S)-1-phenylethyl]azetidin-2-one
-
0.01 mM, 87% inhibition
(4S)-3-[(1R,2S)-2-azido-1-hydroxybutyl]-3-[(S)-hydroxy(phenyl)methyl]-4-phenyl-1-[(1S)-1-phenylethyl]azetidin-2-one
-
87% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested
(4S)-3-[(1S,2R)-2-azido-1-hydroxybutyl]-3-[(R)-hydroxy(phenyl)methyl]-4-phenyl-1-[(1S)-1-phenylethyl]azetidin-2-one
-
79% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested
(4S)-3-[(1S,2R)-2-azido-1-hydroxybutyl]-3-[(S)-hydroxy(phenyl)methyl]-4-phenyl-1-[(1S)-1-phenylethyl]azetidin-2-one
-
0.01 mM, 79% inhibition
(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid
-
-
(6R,9S,13S)-3-benzyl-9-(diphenylmethyl)-6-methyl-13-[(1S)-1-methylpentyl]-1-oxa-4,7,10-triazacyclotridecane-2,5,8,11-tetrone
-
inhibition of both isoforms ACAT1 and ACAT2; inhibition of both isoforms ACAT1 and ACAT2
(6S,9S,13R)-9-(2-chlorobenzyl)-6-methyl-3-[(1S)-1-methylpropyl]-13-pentyl-1-oxa-4,7,10-triazacyclotridecane-2,5,8,11-tetrone
-
; selective inhibition of isoform ACAT1
(6S,9S,13S)-6-methyl-13-[(1S)-1-methylnonyl]-3-[(1S)-1-methylpropyl]-9-(naphthalen-2-ylmethyl)-1-oxa-4,7,10-triazacyclotridecane-2,5,8,11-tetrone
-
; selective inhibition of isoform ACAT2
(6S,9S,13S)-6-methyl-9-(4-methylbenzyl)-13-[(1S)-1-methylbutyl]-3-[(1S)-1-methylpropyl]-1-oxa-4,7,10-triazacyclotridecane-2,5,8,11-tetrone
-
; selective inhibition of isoform ACAT1
(6S,9S,13S)-9-(3-chlorobenzyl)-6-methyl-13-[(1S)-1-methylbutyl]-3-[(1S)-1-methylpropyl]-1-oxa-4,7,10-triazacyclotridecane-2,5,8,11-tetrone
-
; selective inhibition of isoform ACAT1
(6S,9S,13S)-9-(diphenylmethyl)-6-methyl-13-[(1S)-1-methylpentyl]-3-[(1R)-1-methylpropyl]-1-oxa-4,7,10-triazacyclotridecane-2,5,8,11-tetrone
-
; selective inhibition of isoform ACAT2
(6S,9S,13S)-9-(diphenylmethyl)-6-methyl-13-[(1S)-1-methylpentyl]-3-[(1S)-1-methylpropyl]-1-oxa-4,7,10-triazacyclotridecane-2,5,8,11-tetrone
-
; selective inhibition of isoform ACAT2
(S)-2',3',5'-trimethyl-4'-hydroxy-alpha-dodecylthio-alpha-phenylacetanilide
-
i.e. F12511, may have direct antiatherosclerotic effects on the cells of the vascular wall
(S)-7-dimethylamino-N-(4-hydroxy-2,3,5-trimethylphenyl)-2-isobutyryl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
-
shows about 16fold stronger anti-foam cell formation activity, 3fold stronger hepatic ACAT inhibitory activity, similar anti-low density lipoprotein (LDL) oxidative activity and 2fold more potent protective activity against macrophage cell death by oxidative stress in comparison with Pactimibe
(S)-N-(2,6-diisopropylphenyl)-2-octanoyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
-
ratio IC50 of pactimibe/IC50 of test compound: 2.2
(S)-N-(4-amino-2,6-diisopropylphenyl)-2-octanoyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide hydrochloride
-
ratio IC50 of pactimibe/IC50 of test compound: 0.96
(S)-N-(4-hydroxy-2,3,5-trimethylphenyl)-2-octanoyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
-
ratio IC50 of pactimibe/IC50 of test compound: 10
(Z)-17(20)-dehydrocholesterol
-
inhibits esterification of endogenous cholesterol
1-(2,6-diisopropyl-phenyl)-3-[4-(4'-nitrophenylthio)phenyl] urea
-
VULM 1457
1-(3,6-dimethylpyrazin-2-yl)-4-(5-phenylpyridazin-3-yl)-1,4-diazepane
-
0.1 mg/ml, 62% inhibition
1-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,2,4a,8a-tetrahydro-1,8-naphthyridin-3-yl]-3-{4-[(ethylamino)methyl]-2,6-bis(1-methylethyl)phenyl}urea
-
IC50: 680 nM
1-[2,4-bis(1-methylethyl)pyridin-3-yl]-3-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,2,4a,8a-tetrahydro-1,8-naphthyridin-3-yl]urea
-
IC50: 5.4 nM
1-[3-amino-2,6-bis(1-methylethyl)phenyl]-3-{1-butyl-4-[3-(3-hydroxypropoxy)phenyl]-2-oxo-1,2,4a,8a-tetrahydro-1,8-naphthyridin-3-yl}urea
-
IC50: 43 nM
1-[4-(aminomethyl)-2,6-bis(1-methylethyl)phenyl]-3-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,2,4a,8a-tetrahydro-1,8-naphthyridin-3-yl]urea
-
IC50: 382 nM
1-[4-amino-2,6-bis(1-methylethyl)phenyl]-3-(1-butyl-4-{3-[3-(ethylamino)propoxy]phenyl}-2-oxo-1,2,4a,8a-tetrahydro-1,8-naphthyridin-3-yl)urea
-
IC50: 452 nM
1-[4-amino-2,6-bis(1-methylethyl)phenyl]-3-{1-butyl-2-oxo-4-[3-(3-piperidin-1-ylpropoxy)phenyl]-1,2,4a,8a-tetrahydro-1,8-naphthyridin-3-yl}urea
-
IC50: 540 nM
1-[4-amino-2,6-bis(1-methylethyl)phenyl]-3-{1-butyl-2-oxo-4-[3-(3-pyrrolidin-1-ylpropoxy)phenyl]-1,2,4a,8a-tetrahydro-1,8-naphthyridin-3-yl}urea
-
IC50: 427 nM
1-[4-amino-2,6-bis(1-methylethyl)phenyl]-3-{1-butyl-4-[3-(3-hydroxypropoxy)phenyl]-2-oxo-1,2,4a,8a-tetrahydro-1,8-naphthyridin-3-yl}urea
-
i.e. SMP-797, possessing a potent ACAT inhibitory activity and significantly enhanced aqueous solubility under acidic conditions. The compound is a promising agent for oral treatment of hypercholesterolemia.IC50: 21 nM
1-[4-amino-2,6-bis(1-methylethyl)phenyl]-3-{1-butyl-4-[3-(4-hydroxybutoxy)phenyl]-2-oxo-1,2,4a,8a-tetrahydro-1,8-naphthyridin-3-yl}urea
-
IC50: 61 nM
1-[4-amino-2,6-di(propan-2-yl)phenyl]-3-({1-[2-(3-hydroxypropoxy)phenyl]-4-(3-methoxyphenyl)piperidin-4-yl}methyl)urea
-
-
1-[4-amino-2,6-di(propan-2-yl)phenyl]-3-{[1-(2-butoxyphenyl)-4-(3-methoxyphenyl)piperidin-4-yl]methyl}urea
17alpha-hydroxyprogesterone
-
-
2,3,6,8-tetramethoxy-5-(piperidin-1-ylsulfonyl)-1,4-dihydro-9H-xanthen-9-one
-
10 microgram/ml, 10.53% inhibition
2,3,6,8-tetramethoxy-5-[(4-phenyl-3,6-dihydropyridin-1(2H)-yl)sulfonyl]-1,4-dihydro-9H-xanthen-9-one
-
10 microgram/ml, 51.34% inhibition
2,3,6,8-tetramethoxy-5-{[4-(3-methylphenyl)piperazin-1-yl]sulfonyl}-1,4-dihydro-9H-xanthen-9-one
-
10 microgram/ml, 64.8% inhibition
2,3,6,8-tetramethoxy-5-{[4-(4-methoxyphenyl)piperazin-1-yl]sulfonyl}-1,4-dihydro-9H-xanthen-9-one
-
10 microgram/ml, 36.92% inhibition
2,3,6,8-tetramethoxy-5-{[4-(pyridin-2-yl)piperazin-1-yl]sulfonyl}-1,4-dihydro-9H-xanthen-9-one
-
10 microgram/ml, 43.56% inhibition
2,3,6,8-tetramethoxy-9-oxo-N-(2-phenylpropyl)-4,9-dihydro-1H-xanthene-5-sulfonamide
-
10 microgram/ml, 10.78% inhibition
2,3,6,8-tetramethoxy-N-(naphthalen-2-ylmethyl)-9-oxo-4,9-dihydro-1H-xanthene-5-sulfonamide
-
10 microgram/ml, 25% inhibition
2-[(2E,6Z,8E,10E)-dodeca-2,6,8,10-tetraenoylamino]-1,1-dimethylethyl acetate
-
IC50: 0.0281 mM; IC50: 0.0875 mM
2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide
-
K-604
20-Methylcholesterol
-
inhibits esterification of endogenous cholesterol
20alpha-hydroxypregn-4-en-3-one
-
-
2alpha,3beta,23-trihydroxyolean-12-en-28-oic acid
-
arjunolic acid, at 0.1 mg/ml, 60.8% inhibition of isoform ACAT1, 5.3% inhibition of isoform ACAT2
2alpha,3beta-dihydroxyolean-12-en-28-oic acid
-
maslinic acid, at 0.1 mg/ml, 46.2% inhibition of isoform ACAT1, 17.3% inhibition of isoform ACAT2
-
2alpha,3beta-dihydroxyurs-12-en-28-oic acid
-
corosolic acid, at 0.1 mg/ml, 46.7% inhibition of isoform ACAT1, 3% inhibition of isoform ACAT2
-
3-(2,4-difluorophenyl)-1-heptyl-1-[5-[(5-phenylpyridazin-3-yl)amino]pentyl]urea
-
0.05 mg/ml, 46% inhibition
3-(2,4-difluorophenyl)-1-heptyl-1-[5-[(5-phenylpyridazin-3-yl)sulfanyl]pentyl]urea
-
0.05 mg/ml, 75% inhibition
3-(2,4-difluorophenyl)-1-heptyl-1-[5-[(5-phenylpyridazin-3-yl)sulfinyl]pentyl]urea
-
0.05 mg/ml, 62% inhibition
3-(2,4-difluorophenyl)-1-heptyl-1-[5-[(5-phenylpyridazin-3-yl)sulfonyl]pentyl]urea
-
0.05 mg/ml, 67% inhibition
3-(2,4-difluorophenyl)-1-heptyl-1-[5-[(6-phenylpyridazin-3-yl)amino]pentyl]urea
-
0.05 mg/ml, 89% inhibition
3-(2,4-difluorophenyl)-1-heptyl-1-[5-[(6-phenylpyridazin-3-yl)sulfinyl]pentyl]urea
-
0.05 mg/ml, 55% inhibition
3-(2,4-difluorophenyl)-1-heptyl-1-[5-[(6-phenylpyridazin-3-yl)sulfonyl]pentyl]urea
-
0.05 mg/ml, 43% inhibition
3-(2,4-difluorophenyl)-1-octyl-1-[5-[(6-phenylpyridazin-3-yl)sulfanyl]pentyl]urea
-
0.05 mg/ml, 44% inhibition
3-(2,4-difluorophenyl)-1-[5-[(5,6-diphenylpyridazin-3-yl)amino]pentyl]-1-heptylurea
-
0.05 mg/ml, 87% inhibition
3-(2,4-difluorophenyl)-1-[5-[(5,6-diphenylpyridazin-3-yl)sulfanyl]pentyl]-1-heptylurea
-
0.05 mg/ml, 75% inhibition
3-(2,4-difluorophenyl)-1-[5-[(5,6-diphenylpyridazin-3-yl)sulfinyl]pentyl]-1-heptylurea
-
0.05 mg/ml, 65% inhibition
3-(2,4-difluorophenyl)-1-[5-[(5,6-diphenylpyridazin-3-yl)sulfonyl]pentyl]-1-heptylurea
-
0.05 mg/ml, 70% inhibition
3-[4-(3,6-dimethylpyrazin-2-yl)piperazin-1-yl]-5-phenylpyridazine
-
0.1 mg/ml, 57% inhibition
3beta,23-dihydroxyurs-12-en-28-oic acid
-
23-hydroxyursolic acid, at 0.1 mg/ml, 41.5% inhibition of isoform ACAT1, 22.2% inhibition of isoform ACAT2
3beta-hydroxylup-20(29)-en-28-oic acid
-
-
3beta-hydroxyolean-12-en-28-oic acid
-
oleanoic acid, at 0.1 mg/ml, 22.6% inhibition of isoform ACAT1, 10.2% inhibition of isoform ACAT2
3beta-hydroxyurs-12-en-28-al
-
ursolic aldehyde, at 0.1 mg/ml, 21.8% inhibition of isoform ACAT1, 13% inhibition of isoform ACAT2
3beta-hydroxyurs-12-en-28-oic acid
-
ursolic acid, at 0.1 mg/ml, 23.1% inhibition of isoform ACAT1, 16.7% inhibition of isoform ACAT2
5,5'-dibutoxy-2,2'-bifuran
-
-
5,5'-dithiobis-(2-nitrobenzoate)
-
50% inhibition of ACAT1 at 0.01 mM
5-(1-butoxy-2-{4-[(2S,3R,4S,5R)-5-(3,4-dimethoxyphenyl)-3,4-dimethyltetrahydrofuran-2-yl]-2-methoxyphenoxy}propyl)-1,3-benzodioxole
-
0.125 mM, 28% inhibition; IC50: 0.017 mM
5-(2-{4-[(2S,3R,4S,5R)-5-(3,4-dimethoxyphenyl)-3,4-dimethyltetrahydrofuran-2-yl]-2-methoxyphenoxy}-1-ethoxypropyl)-1,3-benzodioxole
-
0.125 mM, 29% inhibition; IC50: 0.031 mM
5-(2-{4-[(2S,3R,4S,5R)-5-(3,4-dimethoxyphenyl)-3,4-dimethyltetrahydrofuran-2-yl]-2-methoxyphenoxy}-1-methoxypropyl)-1,3-benzodioxole
-
0.125 mM, 45% inhibition; IC50: 0.035 mM
5-(2-{4-[(2S,3R,4S,5R)-5-(3,4-dimethoxyphenyl)-3,4-dimethyltetrahydrofuran-2-yl]-2-methoxyphenoxy}-1-propoxypropyl)-1,3-benzodioxole
-
0.125 mM, 33% inhibition; IC50: 0.014 mM
5-[(4-aminopiperazin-1-yl)sulfonyl]-2,3,6,8-tetramethoxy-1,4-dihydro-9H-xanthen-9-one
-
10 microgram/ml, 14.5% inhibition
5-[2-{4-[(2S,3R,4S,5R)-5-(3,4-dimethoxyphenyl)-3,4-dimethyltetrahydrofuran-2-yl]-2-methoxyphenoxy}-1-(heptyloxy)propyl]-1,3-benzodioxole
-
0.125 mM, 26% inhibition; IC50: 0.05 mM
5-[2-{4-[(2S,3R,4S,5R)-5-(3,4-dimethoxyphenyl)-3,4-dimethyltetrahydrofuran-2-yl]-2-methoxyphenoxy}-1-(hexyloxy)propyl]-1,3-benzodioxole
-
0.125 mM, 33% inhibition; IC50: 0.034 mM
5-[2-{4-[(2S,3R,4S,5R)-5-(3,4-dimethoxyphenyl)-3,4-dimethyltetrahydrofuran-2-yl]-2-methoxyphenoxy}-1-(nonyloxy)propyl]-1,3-benzodioxole
-
0.125 mM, 10% inhibition; 0.125 mM, 25% inhibition
5-[2-{4-[(2S,3R,4S,5R)-5-(3,4-dimethoxyphenyl)-3,4-dimethyltetrahydrofuran-2-yl]-2-methoxyphenoxy}-1-(octyloxy)propyl]-1,3-benzodioxole
-
0.125 mM: 19% inhibition; 0.125 mM: 44% inhibition
5-[2-{4-[(2S,3R,4S,5R)-5-(3,4-dimethoxyphenyl)-3,4-dimethyltetrahydrofuran-2-yl]-2-methoxyphenoxy}-1-(pentyloxy)propyl]-1,3-benzodioxole
-
0.125 mM, 33% inhibition; IC50: 0.02 mM
5-{[(2R,6S)-2,6-dimethylmorpholin-4-yl]sulfonyl}-2,3,6,8-tetramethoxy-1,4-dihydro-9H-xanthen-9-one
-
10 microgram/ml, 8.84% inhibition
5-{[3-(dimethylamino)pyrrolidin-1-yl]sulfonyl}-2,3,6,8-tetramethoxy-1,4-dihydro-9H-xanthen-9-one
-
10 microgram/ml, 20.96% inhibition
5alpha,8alpha-epidioxy-24(R)-methylcholesta-6,22-diene-3beta-ol
-
-
5alpha-Cholest-8(14)-en-3beta-ol-15-one
-
inhibits the esterification of cholesterol
5alpha-dihydroprogesterone
Acetic anhydride
-
2 distinct tissue types with difference in reactivity, the inhibitor appears to modify a histidine residue
acetone
acetylshikonin
-
-
acyl-CoA binding protein
-
3fold decrease in activity
-
acyl-CoA binding protein/oleoyl-CoA complexes
-
strongly inhibit
-
ADP
-
inactivates
AM-251
-
selective antagonist of cannobinoid receptor CB1. Additionally, reatment of cells reduces cholesteryl ester synthesis in unstimulated and acetylated low densitixy lipoprotein-stimulated Raw 264.7 macrophages, CB2 +/+ and CB2-/- peritoneal macrophages, as well as in vitro, in mouse liver microsomes. Consistent with inhibition of ACAT, the development of foam cell characteristics in macrophages by treatment with acetylated low density lipoprotein is reduced
androstenedione
-
-
androsterone
-
inhibits esterification of endogenous cholesterol
ATP
-
inactivates
aurasperone A
-
isolation from the culture broth of Aspergillus species; isolation from the culture broth of Aspergillus species
aurasperone D
-
isolation from the culture broth of Aspergillus species; isolation from the culture broth of Aspergillus species
avasimibe
averufanin
-
isolation from the culture broth of Aspergillus species; isolation from the culture broth of Aspergillus species
beauvericin
beauveriolide I
beauveriolide III
beta-hydroxyisovalerylshikonin
-
-
beta-sanshool
-
extracted from Zanthoxylum piperitum DC; IC50: 0.012 mM; IC50: 0.039 mM
beta-sanshool acetate
-
semi-synthetic compound
betulin
-
; IC50: 0.083 mM, hACAT-1
bovine serum albumin
butanol
cholestyramine
CI-1011
-
-
CI-976
CL-283,546
CP113818
-
recombinant enzyme, 80-90% inhibition at 0.0002 mM
Cycloartenol
-
inhibits esterification of exogenous cholesterol
dehydroisoandrosterone
-
-
dehydropipernonaline
dehydroretrofractamide
deoxycorticosterone
Detergents
diazepam
-
competes with oleoyl-CoA for its binding to microsomal membranes
diethyl dicarbonate
-
2 distinct tissue types with difference in reactivity, DEP-sensitive subtype typified by aortic ACTAT, DEP-resistant subtype typified by liver ACAT, irreversible inhibition, the inhibitor appear to modify a histidine residue
DuP 128
ergosterol
-
inhibits esterification of exogenous cholesterol
esculeogenin A
esculeoside A
-
-
estradiol-17beta
-
-
ethanol
ethyl 1-[(2,3,6,8-tetramethoxy-9-oxo-4,9-dihydro-1H-xanthen-5-yl)sulfonyl]piperidine-3-carboxylate
-
10 microgram/ml, 7.99% inhibition
ethyl N-methyl-N-[(2,3,6,8-tetramethoxy-9-oxo-4,9-dihydro-1H-xanthen-5-yl)sulfonyl]glycinate
-
10 microgram/ml, 16.79% inhibition
F12511
-
;
flavasperone
-
isolation from the culture broth of Aspergillus species, selective for isoform ACAT2
gamma-sanshool
-
extracted from Zanthoxylum piperitum DC; IC50: 0.0797 mM; IC50: 0.0826 mM
GERI-BP001M
-
0.1 mg/ml, 82% inhibition
GERIBP001M
-
0.05 mM, 83% inhibition
glabrol
glisoprenin A
HWY-289
-
50% inhibition at 0.0132 mM
hydroxy-beta-sanshool
-
low inhibition; low inhibition
Inhibitor from rabbit liver
-
fatty acid ester, mostly stearate, of a pentacyclic triterpene acid, irreversible inhibition, which is prevented by incubation with bovine serum albumin, half-maximal inhibition occurs at an inhibitor concentration of 0.02 mM
-
isobutyrylshikonin
-
-
K-604
selective for isoform ACAT-1, use to measure the individual enzymatic activities of isoforms ACAT-1 and ACAT-2; selective for isoform ACAT-1, use to measure the individual enzymatic activities of isoforms ACAT-1 and ACAT-2
K97-0239A
K97-0239B
lanosterol
lidocaine
lupeol
-
; IC50: 0.048 mM, hACAT-1
manassantin B
inhibition of both isoforms ACAT-1 and ACAT-2; inhibition of both isoforms ACAT-1 and ACAT-2
methyl N-[(2,3,6,8-tetramethoxy-9-oxo-4,9-dihydro-1H-xanthen-5-yl)sulfonyl]glycinate
-
10 microgram/ml, 5.13% inhibition
MgATP2-
miconazole
-
50% inhibition at 0.0224 mM
N'-(3,6-dimethylpyrazin-2-yl)-N,N-diheptylbutane-1,4-diamine
-
0.1 mg/ml, 55% inhibition
N'-(3,6-dimethylpyrazin-2-yl)-N,N-diheptylpentane-1,5-diamine
-
0.1 mg/ml, 58% inhibition
N'-(3,6-dimethylpyrazin-2-yl)-N,N-diheptylpropane-1,3-diamine
-
0.1 mg/ml, 52% inhibition
N'-(3,6-dimethylpyrazin-2-yl)-N-heptyl-N-(5-phenylpyridazin-3-yl)butane-1,4-diamine
-
0.1 mg/ml, 87% inhibition
N'-(3,6-dimethylpyrazin-2-yl)-N-heptyl-N-(5-phenylpyridazin-3-yl)heptane-1,7-diamine
-
0.1 mg/ml, 58% inhibition
N'-(3,6-dimethylpyrazin-2-yl)-N-heptyl-N-(5-phenylpyridazin-3-yl)hexane-1,6-diamine
-
0.1 mg/ml, 79% inhibition; 0.1 mg/ml, 95% inhibition
N'-(3,6-dimethylpyrazin-2-yl)-N-heptyl-N-(5-phenylpyridazin-3-yl)octane-1,8-diamine
-
0.1 mg/ml, 76% inhibition
N'-(3,6-dimethylpyrazin-2-yl)-N-heptyl-N-(5-phenylpyridazin-3-yl)pentane-1,5-diamine
-
0.1 mg/ml, 79% inhibition
N'-(3,6-dimethylpyrazin-2-yl)-N-heptyl-N-(5-phenylpyridazin-3-yl)propane-1,3-diamine
-
0.1 mg/ml, 70% inhibition
N,N-diethyl-1-[(2,3,6,8-tetramethoxy-9-oxo-4,9-dihydro-1H-xanthen-5-yl)sulfonyl]piperidine-3-carboxamide
-
10 microgram/ml, 12.59% inhibition
N-(3,6-dimethylpyrazin-2-yl)-N'-(5-phenylpyridazin-3-yl)hexane-1,6-diamine
-
0.1 mg/ml, 89% inhibition
N-(3-chlorobenzyl)-2,3,6,8-tetramethoxy-9-oxo-4,9-dihydro-1H-xanthene-5-sulfonamide
-
10 microgram/ml, 15.76% inhibition
N-(4,6-dimethyl-1-pentylindolin-7-yl)-2,2-dimethylpropanamide
-
KY-455, an anti-oxidative ACAT inhibitor
N-(4-amino-2, 6-diisopropylphenyl)-N'-[1-butyl-4-[3-(3-hydroxypropoxy) phenyl]-2-oxo-1,2-dihydro-1,8-naphthyridin-3-yl] urea hydrochloride monohydrate
-
SMP-797
N-(4-fluorobenzyl)-2,3,6,8-tetramethoxy-9-oxo-4,9-dihydro-1H-xanthene-5-sulfonamide
-
10 microgram/ml, 10.24% inhibition
N-(5,6-diphenylpyridazin-3-yl)-N'-(5-phenylpyridazin-3-yl)hexane-1,6-diamine
-
0.1 mg/ml, 88% inhibition
N-(5-phenylpyridazin-3-yl)hexane-1,6-diamine
-
0.1 mg/ml, 72% inhibition
N-(6-chloropyridazin-3-yl)-N'-(5-phenylpyridazin-3-yl)hexane-1,6-diamine
-
0.1 mg/ml, 83% inhibition
N-(6-methoxypyridazin-3-yl)-N'-(5-phenylpyridazin-3-yl)hexane-1,6-diamine
-
0.1 mg/ml, 83% inhibition
N-(benzyloxy)-2,3,6,8-tetramethoxy-9-oxo-4,9-dihydro-1H-xanthene-5-sulfonamide
-
10 microgram/ml, 16.76% inhibition
N-ethylmaleimide
-
50% inhibition of ACAT1 at 0.5 mM
N-[2-(3,4-dimethylphenyl)ethyl]-2,3,6,8-tetramethoxy-9-oxo-4,9-dihydro-1H-xanthene-5-sulfonamide
-
10 microgram/ml, 11.86% inhibition
N-[3-(3,4-dimethoxyphenyl)propyl]-2,3,6,8-tetramethoxy-N-methyl-9-oxo-4,9-dihydro-1H-xanthene-5-sulfonamide
-
10 microgram/ml, 30.06% inhibition
naphthalene-1-carboxylic acid [3-(6-bromo-imidazo[1,2-a]pyridin-2-yl)-phenyl]-amide
-
48% inhibition at 0.025 mg/ml
naphthalene-2-carboxylic acid (3-[6-(2,4-difluoro-phenyl)-imidazo[1,2-a]pyridin-2-yl]-phenyl)-amide
-
23.6% inhibition at 0.025 mg/ml
naphthalene-2-carboxylic acid [3-(6-bromo-imidazo[1,2-a]pyridin-2-yl)-phenyl]-amide
-
56% inhibition at 0.025 mg/ml
naphthalene-2-carboxylic acid [3-(6-naphtalen-2-yl-imidazo-[1,2-a]pyridin-2-yl)-phenyl]-amide
-
7.1% inhibition at 0.025 mg/ml
octimibate
-
inhibits
oleic acid anilide
-
-
oleoyl-CoA
-
inhibits at high concentrations, the inhibition is prevented by serum albumin
Organic solvents
p-chloromercuribenzene sulfonic acid
-
50% inhibition of ACAT1 at 0.01 mM, Cys467 is one of the major targets for inhibition
p-mercuribenzoate
-
100% inhibition of liver and aortic enzyme at 1 mM
pactimibe sulfate
PD138412
-
recombinant enzyme, 80-90% inhibition at 0.003 mM
-
pellitorin
phenochalasin A
Phenylglyoxal
-
concentration-dependent inhibition of liver enzyme with 65% inhibition at 5 mM
phosphatidylinositol
-
-
phosphatidylserine
piperchabamide D
pipercide
Polyoxyethylated cholesterol
-
-
-
Pregn-5-en-3beta-ol
-
inhibits esterification of endogenous cholesterol
pregnenolone
progesterone
purpactin A
purpactin B
purpactin C
pyripyropene A
pyripyropene B
pyripyropene C
pyripyropene D
retrofractamide A
saucemeol B
-
0.125 mM, 57% inhibition; IC50: 0.043 mM
SC-31769
sespendole
shikonin
-
-
sitosterol
-
inhibits esterification of exogenous cholesterol
SM-32504
-
IC50: 11 nM
sphingomyelin
-
-
spylidone
SR144528
-
selective antagonist of cannobinoid receptor CB1. Additionally, reatment of cells reduces cholesteryl ester synthesis in unstimulated and acetylated low densitixy lipoprotein-stimulated Raw 264.7 macrophages, CB2 +/+ and CB2-/- peritoneal macrophages, as well as in vitro, in mouse liver microsomes. Consistent with inhibition of ACAT, the development of foam cell characteristics in macrophages by treatment with acetylated low density lipoprotein is reduced
stanolone
-
inhibits esterification of endogenous cholesterol
sterigmatocystin
-
; isolation from the culture broth of Aspergillus species, selective for isoform ACAT2
stigmasterol
-
inhibits esterification of exogenous cholesterol
terpendole C
testosterone
Tetracaine
Tetranitromethane
-
100% inhibition of liver and aortic enzyme at 1 mM
Triton WR1339
-
90% inhibition at 0.3% wt./vol.
VULM 1457
-
-
YM-750
-
-
[4-(2-(3-[(naphthalene-2-carbonyl)-amino]-phenyl)-imidazo[1,2-a]pyridin-6-yl)-phenoxy]-acetic acid
-
15% inhibition at 0.025 mg/ml
[4-(2-(3-[(naphthalene-2-carbonyl)-amino]-phenyl)-imidazo[1,2-a]pyridin-6-yl)-phenoxy]-acetic acid ethyl ester
-
8.7% inhibition at 0.025 mg/ml
[7-(2,2-dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl]acetic acid hemisulfate
-
pactimibe sulfate
additional information
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
25-hydroxycholesterol
6-ketocholestanol
-
added at high concentration causes modest increase in enzyme activity
7-ketocholesterol
-
added at high concentration causes modest increase in enzyme activity
7-oxocholesterol
-
-
albumin
ATP
-
slight stimulation
cholate
-
increase of activity in cholate-fed animals
cholesterol
liver fatty acid binding protein/bovine serum albumin
-
small increase in activity
-
low density lipoprotein
Mevalonolactone
-
intragastric administration, increasing sterol biosynthesis and increasing enzyme activity
phosphatidylethanolamine
-
weak stimulatory effect on activity
sitosterol
-
; weak activator
TNF-alpha
-
up-regulating of ACAT1 expression
-
additional information
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00163 - 0.06
cholesterol
0.0022
Elaidoyl-CoA
-
-
0.0028
linoleoyl-CoA
-
-
0.0013 - 0.069
oleoyl-CoA
0.00000266 - 0.00001218
oleyl-CoA
0.038
palmitoyl-CoA
-
-
0.0012
pregnenolone
-
pH 7.4, 37C, with cholesterol (0.32 mM). Without cholesterol, the Km for pregnenolone is too high to be measurable
0.0064
stearoyl-CoA
-
pH and temperature not specified in the publication
additional information
additional information
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00006 - 0.00009
(6R,9S,13S)-3-benzyl-9-(diphenylmethyl)-6-methyl-13-[(1S)-1-methylpentyl]-1-oxa-4,7,10-triazacyclotridecane-2,5,8,11-tetrone
0.001 - 0.04
(6S,9S,13R)-9-(2-chlorobenzyl)-6-methyl-3-[(1S)-1-methylpropyl]-13-pentyl-1-oxa-4,7,10-triazacyclotridecane-2,5,8,11-tetrone
0.00025 - 0.02
(6S,9S,13S)-6-methyl-13-[(1S)-1-methylnonyl]-3-[(1S)-1-methylpropyl]-9-(naphthalen-2-ylmethyl)-1-oxa-4,7,10-triazacyclotridecane-2,5,8,11-tetrone
0.0001 - 0.004
(6S,9S,13S)-6-methyl-9-(4-methylbenzyl)-13-[(1S)-1-methylbutyl]-3-[(1S)-1-methylpropyl]-1-oxa-4,7,10-triazacyclotridecane-2,5,8,11-tetrone
0.00015 - 0.0065
(6S,9S,13S)-9-(3-chlorobenzyl)-6-methyl-13-[(1S)-1-methylbutyl]-3-[(1S)-1-methylpropyl]-1-oxa-4,7,10-triazacyclotridecane-2,5,8,11-tetrone
0.0001 - 0.004
(6S,9S,13S)-9-(diphenylmethyl)-6-methyl-13-[(1S)-1-methylpentyl]-3-[(1R)-1-methylpropyl]-1-oxa-4,7,10-triazacyclotridecane-2,5,8,11-tetrone
0.00027 - 0.01
(6S,9S,13S)-9-(diphenylmethyl)-6-methyl-13-[(1S)-1-methylpentyl]-3-[(1S)-1-methylpropyl]-1-oxa-4,7,10-triazacyclotridecane-2,5,8,11-tetrone
0.000378
2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide
-
inhibition is competitive with respect to oleoyl-coenzyme A
0.05
20alpha-hydroxypregn-4-en-3-one
-
-
0.5 - 5
Acetic anhydride
0.026
CI-976
-
-
0.04 - 1.5
diethyl dicarbonate
0.00515
HWY-289
-
-
0.039
miconazole
-
-
0.05
progesterone
-
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0138 - 0.0251
(1R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl 3-methylbutanoate
0.0537 - 0.0562
(1R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl benzoate
0.0496 - 0.0776
(1R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl butanoate
0.0307 - 0.0714
(1R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl pent-4-enoate
0.0845 - 0.0948
(1R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl pentanoate
0.0224 - 0.0287
(1R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl propanoate
0.025 - 0.102
(24R)-ethylcholest-5-ene-3,7-diol
0.000025 - 0.000062
(3S,4R,4aS,6S,6aS,12R,12aR,12bR)-12,12b-dihydroxy-4,6a-dimethyl-4-[[(methylsulfonyl)oxy]methyl]-11-oxo-6-(pentanoyloxy)-9-pyridin-3-yl-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromen-3-yl benzoate
0.00001 - 0.00007
(3S,4R,4aS,6S,6aS,12R,12aR,12bR)-12,12b-dihydroxy-4,6a-dimethyl-4-[[(methylsulfonyl)oxy]methyl]-11-oxo-9-pyridin-3-yl-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromene-3,6-diyl dipentanoate
0.000006 - 0.0035
(3S,4R,4aS,6S,6aS,12R,12aR,12bR)-3-(acetyloxy)-4-[(acetyloxy)methyl]-12,12b-dihydroxy-4,6a-dimethyl-11-oxo-9-pyridin-3-yl-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromen-6-yl 3-methylbutanoate
0.00007 - 0.08
(3S,4R,4aS,6S,6aS,12R,12aR,12bR)-4-[(acetyloxy)methyl]-12,12b-dihydroxy-4,6a-dimethyl-11-oxo-9-pyridin-3-yl-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromene-3,6-diyl diacetate
0.000012 - 0.0028
(3S,4R,4aS,6S,6aS,12R,12aR,12bR)-4-[(acetyloxy)methyl]-3-(butanoyloxy)-12,12b-dihydroxy-4,6a-dimethyl-11-oxo-9-pyridin-3-yl-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromen-6-yl hexanoate
0.00001 - 0.0042
(3S,4S,4aR,6S,6aS,12R,12aR,12bR)-3-(acetyloxy)-4-[(acetyloxy)methyl]-4,12,12b-trihydroxy-6a-methyl-11-oxo-9-pyridin-3-yl-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromen-6-yl (2E)-pent-2-enoate
0.0007
(4aR,4bS,6S,6aS,12R,12aR,12bR,14aS)-12,12b-dihydroxy-4a,6a-dimethyl-2-(1-methylethyl)-11-oxo-9-pyridin-3-yl-4,4a,4b,5,6,6a,12,12a,12b,13,14,14a-dodecahydro-11H-pyrano[4',3':2,3]chromeno[6,5-f][1,3]benzodioxin-6-yl pentanoate
Chlorocebus aethiops
-
isoform ACAT1, cell-based assay
0.00001 - 0.0032
(4aR,4bS,6S,6aS,12R,12aR,12bR,14aS)-12,12b-dihydroxy-4a,6a-dimethyl-2-(2-methylphenyl)-11-oxo-9-pyridin-3-yl-4,4a,4b,5,6,6a,12,12a,12b,13,14,14a-dodecahydro-11H-pyrano[4',3':2,3]chromeno[6,5-f][1,3]benzodioxin-6-yl pentanoate
0.0038
(4aR,4bS,6S,6aS,12R,12aR,12bR,14aS)-12,12b-dihydroxy-4a,6a-dimethyl-2-(4-methylphenyl)-11-oxo-9-pyridin-3-yl-4,4a,4b,5,6,6a,12,12a,12b,13,14,14a-dodecahydro-11H-pyrano[4',3':2,3]chromeno[6,5-f][1,3]benzodioxin-6-yl pentanoate
Chlorocebus aethiops
-
isoform ACAT1, cell-based assay
0.000113
(S)-7-dimethylamino-N-(4-hydroxy-2,3,5-trimethylphenyl)-2-isobutyryl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
Oryctolagus cuniculus
-
pH 7.4, 37C
0.00068
1-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,2,4a,8a-tetrahydro-1,8-naphthyridin-3-yl]-3-{4-[(ethylamino)methyl]-2,6-bis(1-methylethyl)phenyl}urea
Rattus norvegicus
-
IC50: 680 nM
0.0000054
1-[2,4-bis(1-methylethyl)pyridin-3-yl]-3-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,2,4a,8a-tetrahydro-1,8-naphthyridin-3-yl]urea
Rattus norvegicus
-
IC50: 5.4 nM
0.000043
1-[3-amino-2,6-bis(1-methylethyl)phenyl]-3-{1-butyl-4-[3-(3-hydroxypropoxy)phenyl]-2-oxo-1,2,4a,8a-tetrahydro-1,8-naphthyridin-3-yl}urea
Rattus norvegicus
-
IC50: 43 nM
0.000382
1-[4-(aminomethyl)-2,6-bis(1-methylethyl)phenyl]-3-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,2,4a,8a-tetrahydro-1,8-naphthyridin-3-yl]urea
Rattus norvegicus
-
IC50: 382 nM
0.000452
1-[4-amino-2,6-bis(1-methylethyl)phenyl]-3-(1-butyl-4-{3-[3-(ethylamino)propoxy]phenyl}-2-oxo-1,2,4a,8a-tetrahydro-1,8-naphthyridin-3-yl)urea
Rattus norvegicus
-
IC50: 452 nM
0.00054
1-[4-amino-2,6-bis(1-methylethyl)phenyl]-3-{1-butyl-2-oxo-4-[3-(3-piperidin-1-ylpropoxy)phenyl]-1,2,4a,8a-tetrahydro-1,8-naphthyridin-3-yl}urea
Rattus norvegicus
-
IC50: 540 nM
0.000427
1-[4-amino-2,6-bis(1-methylethyl)phenyl]-3-{1-butyl-2-oxo-4-[3-(3-pyrrolidin-1-ylpropoxy)phenyl]-1,2,4a,8a-tetrahydro-1,8-naphthyridin-3-yl}urea
Rattus norvegicus
-
IC50: 427 nM
0.000021
1-[4-amino-2,6-bis(1-methylethyl)phenyl]-3-{1-butyl-4-[3-(3-hydroxypropoxy)phenyl]-2-oxo-1,2,4a,8a-tetrahydro-1,8-naphthyridin-3-yl}urea
Rattus norvegicus
-
i.e. SMP-797, possessing a potent ACAT inhibitory activity and significantly enhanced aqueous solubility under acidic conditions. The compound is a promising agent for oral treatment of hypercholesterolemia.IC50: 21 nM
0.000061
1-[4-amino-2,6-bis(1-methylethyl)phenyl]-3-{1-butyl-4-[3-(4-hydroxybutoxy)phenyl]-2-oxo-1,2,4a,8a-tetrahydro-1,8-naphthyridin-3-yl}urea
Rattus norvegicus
-
IC50: 61 nM
0.000018
1-[4-amino-2,6-di(propan-2-yl)phenyl]-3-({1-[2-(3-hydroxypropoxy)phenyl]-4-(3-methoxyphenyl)piperidin-4-yl}methyl)urea
Rattus norvegicus
-
pH 7.4
0.000032
1-[4-amino-2,6-di(propan-2-yl)phenyl]-3-{[1-(2-butoxyphenyl)-4-(3-methoxyphenyl)piperidin-4-yl]methyl}urea
Rattus norvegicus
-
pH 7.4
0.0281 - 0.0875
2-[(2E,6Z,8E,10E)-dodeca-2,6,8,10-tetraenoylamino]-1,1-dimethylethyl acetate
0.000068 - 0.1028
2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide
0.0115 - 0.0339
3beta-hydroxylup-20(29)-en-28-oic acid
0.16 - 0.19
5,5'-dibutoxy-2,2'-bifuran
0.017
5-(1-butoxy-2-{4-[(2S,3R,4S,5R)-5-(3,4-dimethoxyphenyl)-3,4-dimethyltetrahydrofuran-2-yl]-2-methoxyphenoxy}propyl)-1,3-benzodioxole
Homo sapiens
-
IC50: 0.017 mM
0.031
5-(2-{4-[(2S,3R,4S,5R)-5-(3,4-dimethoxyphenyl)-3,4-dimethyltetrahydrofuran-2-yl]-2-methoxyphenoxy}-1-ethoxypropyl)-1,3-benzodioxole
Homo sapiens
-
IC50: 0.031 mM
0.035
5-(2-{4-[(2S,3R,4S,5R)-5-(3,4-dimethoxyphenyl)-3,4-dimethyltetrahydrofuran-2-yl]-2-methoxyphenoxy}-1-methoxypropyl)-1,3-benzodioxole
Homo sapiens
-
IC50: 0.035 mM
0.014
5-(2-{4-[(2S,3R,4S,5R)-5-(3,4-dimethoxyphenyl)-3,4-dimethyltetrahydrofuran-2-yl]-2-methoxyphenoxy}-1-propoxypropyl)-1,3-benzodioxole
Homo sapiens
-
IC50: 0.014 mM
0.05
5-[2-{4-[(2S,3R,4S,5R)-5-(3,4-dimethoxyphenyl)-3,4-dimethyltetrahydrofuran-2-yl]-2-methoxyphenoxy}-1-(heptyloxy)propyl]-1,3-benzodioxole
Homo sapiens
-
IC50: 0.05 mM
0.034
5-[2-{4-[(2S,3R,4S,5R)-5-(3,4-dimethoxyphenyl)-3,4-dimethyltetrahydrofuran-2-yl]-2-methoxyphenoxy}-1-(hexyloxy)propyl]-1,3-benzodioxole
Homo sapiens
-
IC50: 0.034 mM
0.02
5-[2-{4-[(2S,3R,4S,5R)-5-(3,4-dimethoxyphenyl)-3,4-dimethyltetrahydrofuran-2-yl]-2-methoxyphenoxy}-1-(pentyloxy)propyl]-1,3-benzodioxole
Homo sapiens
-
IC50: 0.02 mM
0.0387 - 0.2
5alpha,8alpha-epidioxy-24(R)-methylcholesta-6,22-diene-3beta-ol
0.1122 - 0.1289
acetylshikonin
0.0015 - 0.006
aurasperone A
0.007
aurasperone D
Chlorocebus aethiops
-
isoform ACAT1, 37C, cell-based assay
0.0043 - 0.0235
avasimibe
0.012 - 0.0218
averufanin
0.00013 - 0.002
beauvericin
0.0006 - 0.02
beauveriolide I
0.00041 - 0.02
beauveriolide III
0.1698 - 0.1869
beta-hydroxyisovalerylshikonin
0.012 - 0.039
beta-sanshool
0.0281 - 0.0875
beta-sanshool acetate
0.083
betulin
Homo sapiens
-
IC50: 0.083 mM, hACAT-1
0.01872 - 0.01911
CI-1011
0.00006 - 0.00012
CL-283,546
0.09
dehydropipernonaline
Rattus norvegicus
-
-
0.06
dehydroretrofractamide
Rattus norvegicus
-
-
0.006
flavasperone
Chlorocebus aethiops
-
isoform ACAT2, 37C, cell-based assay
0.0797 - 0.0826
gamma-sanshool
0.0246 - 0.026
glabrol
0.0004 - 0.012
glisoprenin A
0.0575
isobutyrylshikonin
Homo sapiens
-
-
0.1 - 1
K-604
0.0015 - 0.04
K97-0239A
0.0017 - 0.7
K97-0239B
0.048
lupeol
Homo sapiens
-
IC50: 0.048 mM, hACAT-1
0.0000532
N-(4-amino-2,6-diisopropylphenyl)-N'-([1-(2-butoxyphenyl)-4-(3-methoxyphenyl)piperidin-4-yl]-methyl)urea
Rattus norvegicus
-
pH 7.4
0.0152
oleic acid anilide
Homo sapiens
-
inhibited ACAT activity in THP-1 macrophages
0.000312
pactimibe
Oryctolagus cuniculus
-
pH 7.4, 37C
0.002 - 0.0049
pactimibe sulfate
0.0405
pellitorin
Rattus norvegicus
-
-
0.0006 - 0.1
phenochalasin A
0.0135
piperchabamide D
Rattus norvegicus
-
-
0.0037
pipercide
Rattus norvegicus
-
-
0.0009 - 0.0045
purpactin A
0.0022 - 0.022
purpactin B
0.0028 - 0.03
purpactin C
0.00006 - 0.08
pyripyropene A
0.0008 - 0.048
pyripyropene B
0.00035 - 0.04
pyripyropene C
0.0012 - 0.038
pyripyropene D
0.0245
retrofractamide A
Rattus norvegicus
-
-
0.043
saucemeol B
Homo sapiens
-
IC50: 0.043 mM
0.004 - 0.02
sespendole
0.0704 - 0.1382
shikonin
0.000011
SM-32504
Rattus norvegicus
-
IC50: 11 nM
0.000031
SMP-797
Rattus norvegicus
-
-
0.003 - 0.042
spylidone
0.0024 - 0.03
sterigmatocystin
0.0005 - 0.01
terpendole C
0.00069 - 0.0159
[7-(2,2-dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl]acetic acid hemisulfate
additional information
(1R,3R,7R)-1-[(1S)-1-hydroxypropyl]-3,7-diphenyl-6-[(1S)-1-phenylethyl]-2-oxa-6-azaspiro[3.3]heptan-5-one